PMID- 19949578
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20211020
IS  - 1738-5555 (Electronic)
IS  - 1738-5520 (Print)
IS  - 1738-5520 (Linking)
VI  - 39
IP  - 5
DP  - 2009 May
TI  - Efficacy of triple anti-platelet therapy including cilostazol in acute myocardial 
      infarction patients undergoing drug-eluting stent implantation.
PG  - 190-7
LID - 10.4070/kcj.2009.39.5.190 [doi]
AB  - BACKGROUND AND OBJECTIVES: Triple anti-platelet therapy is known to prevent 
      restenosis after drug-eluting stent (DES) implantation. However, there is little 
      available data concerning the efficacy of triple anti-platelet therapy for acute 
      myocardial infarction (AMI). SUBJECTS AND METHODS: We analyzed 528 consecutive 
      patients with AMI undergoing DES implantation between Nov 2005 and Apr 2008. We 
      compared clinical outcomes in the triple anti-platelet therapy (group I, n=413: 
      cilostazol combined with aspirin and clopidogrel for at least one month) and dual 
      antiplatelet therapy groups (group II, n=115: aspirin and clopidogrel). RESULTS: 
      There were no significant differences in baseline characteristics. However, ST 
      elevation myocardial infarction (STEMI) and use of TAXUS(R) stents were more 
      common (70.9% vs. 55.7%, p=0.002; 83.5% vs. 73.0%, p=0.011) in Group I. Group I 
      had lower incidences of cardiac death, 6-month target lesion revascularization 
      (TLR), and major adverse cardiac and cerebrovascular events (MACCE) compared to 
      Group II (1.7% vs. 5.7%, p=0.022; 5.7% vs. 11.5%, 0.035; 7.9% vs. 16.0%, 
      p=0.011). On subgroup analysis, the incidence of 6-month TLR was lower among 
      patients with American College of Cardiology/American Heart Association (ACC/AHA) 
      B2 or C lesions and non-STEMI (6.0% vs. 14.9%, p=0.012; 4.3% vs. 19.1%, p=0.002) 
      in Group I compared to those in Group II. The rates of bleeding complications 
      were no different between the two groups. On multivariate analysis, Killip III or 
      IV and triple anti-platelet therapy were independent predictors of 6-month MACCE 
      hazard ratio (HR)=3.382; 95% confidence interval (CI)=1.384-8.262, HR=0.436; 95% 
      CI=0.203-0.933. CONCLUSION: Triple anti-platelet therapy is safe and 
      efficacious, and it prevents TLR in patients with AMI, especially those with 
      complex lesions and non-STEMIs.
FAU - Park, Keun-Ho
AU  - Park KH
AD  - The Heart Center of Chonnam National University Hospital, Cardiovascular Research 
      Institute of Chonnam National University, Gwangju, Korea.
FAU - Jeong, Myung Ho
AU  - Jeong MH
FAU - Lee, Min Goo
AU  - Lee MG
FAU - Ko, Jum Suk
AU  - Ko JS
FAU - Lee, Shin Eun
AU  - Lee SE
FAU - Kang, Won Yu
AU  - Kang WY
FAU - Kim, Soo Hyun
AU  - Kim SH
FAU - Sim, Doo Sun
AU  - Sim DS
FAU - Yoon, Nam Sik
AU  - Yoon NS
FAU - Youn, Hyun Ju
AU  - Youn HJ
FAU - Hong, Young Joon
AU  - Hong YJ
FAU - Park, Hyung Wook
AU  - Park HW
FAU - Kim, Ju Han
AU  - Kim JH
FAU - Ahn, Youngkeun
AU  - Ahn Y
FAU - Cho, Jeong Gwan
AU  - Cho JG
FAU - Park, Jong Chun
AU  - Park JC
FAU - Kang, Jung Chaee
AU  - Kang JC
LA  - eng
PT  - Journal Article
DEP - 20090528
PL  - Korea (South)
TA  - Korean Circ J
JT  - Korean circulation journal
JID - 101247141
PMC - PMC2771786
OTO - NOTNLM
OT  - Drug-eluting stents
OT  - Myocardial infarction
OT  - Platelets
EDAT- 2009/12/02 06:00
MHDA- 2009/12/02 06:01
PMCR- 2009/05/01
CRDT- 2009/12/02 06:00
PHST- 2008/10/28 00:00 [received]
PHST- 2008/12/10 00:00 [revised]
PHST- 2009/01/01 00:00 [accepted]
PHST- 2009/12/02 06:00 [entrez]
PHST- 2009/12/02 06:00 [pubmed]
PHST- 2009/12/02 06:01 [medline]
PHST- 2009/05/01 00:00 [pmc-release]
AID - 10.4070/kcj.2009.39.5.190 [doi]
PST - ppublish
SO  - Korean Circ J. 2009 May;39(5):190-7. doi: 10.4070/kcj.2009.39.5.190. Epub 2009 
      May 28.